PL2562160T3 - Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczu - Google Patents
Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczuInfo
- Publication number
- PL2562160T3 PL2562160T3 PL11765738T PL11765738T PL2562160T3 PL 2562160 T3 PL2562160 T3 PL 2562160T3 PL 11765738 T PL11765738 T PL 11765738T PL 11765738 T PL11765738 T PL 11765738T PL 2562160 T3 PL2562160 T3 PL 2562160T3
- Authority
- PL
- Poland
- Prior art keywords
- agent
- urine collection
- therapeutic agent
- preventive
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010083723 | 2010-03-31 | ||
EP11765738.7A EP2562160B1 (en) | 2010-03-31 | 2011-03-31 | Therapeutic agent or preventive agent for urine collection disorder |
PCT/JP2011/058220 WO2011125838A1 (ja) | 2010-03-31 | 2011-03-31 | 蓄尿障害の治療剤又は予防剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2562160T3 true PL2562160T3 (pl) | 2015-03-31 |
Family
ID=44762776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11765738T PL2562160T3 (pl) | 2010-03-31 | 2011-03-31 | Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczu |
Country Status (13)
Country | Link |
---|---|
US (1) | US8642625B2 (pl) |
EP (1) | EP2562160B1 (pl) |
JP (1) | JP5783042B2 (pl) |
KR (1) | KR101739879B1 (pl) |
CN (1) | CN102812008B (pl) |
AU (1) | AU2011237074B2 (pl) |
BR (1) | BR112012022944B1 (pl) |
CA (1) | CA2793730C (pl) |
ES (1) | ES2524400T3 (pl) |
MX (1) | MX2012010766A (pl) |
PL (1) | PL2562160T3 (pl) |
RU (1) | RU2559318C2 (pl) |
WO (1) | WO2011125838A1 (pl) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103922928A (zh) * | 2013-10-31 | 2014-07-16 | 北京利和知信科技有限公司 | 适用于制备烯烃聚合催化剂的环取代醚酸酯化合物 |
JP6447496B2 (ja) * | 2014-01-29 | 2019-01-09 | 東レ株式会社 | 多発性硬化症の治療剤又は予防剤 |
CN106243096B (zh) * | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | 三环类药物的新用途 |
US11921476B2 (en) | 2020-08-04 | 2024-03-05 | Marathon Petroleum Company Lp | Systems and methods for holistic low carbon intensity fuel and ethanol production |
US11994259B2 (en) | 2022-10-21 | 2024-05-28 | Marathon Petroleum Company Lp | Renewable diesel interface recombination |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69830728T2 (de) | 1997-04-11 | 2006-05-18 | Nippon Shinyaku Co., Ltd. | Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz |
AUPP608898A0 (en) * | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
US6437146B1 (en) * | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
AU4308300A (en) * | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
WO2007111323A1 (ja) * | 2006-03-27 | 2007-10-04 | Toray Industries, Inc. | ウレイド誘導体およびその医薬用途 |
EP2061775A2 (en) * | 2006-09-13 | 2009-05-27 | Astra Zeneca AB | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
WO2010007943A1 (ja) * | 2008-07-17 | 2010-01-21 | 旭化成ファーマ株式会社 | 含窒素複素環化合物 |
TWI435874B (zh) * | 2008-10-31 | 2014-05-01 | Toray Industries | 環己烷衍生物及其醫藥用途 |
-
2011
- 2011-03-31 CN CN201180016947.6A patent/CN102812008B/zh not_active Expired - Fee Related
- 2011-03-31 RU RU2012146323/04A patent/RU2559318C2/ru not_active IP Right Cessation
- 2011-03-31 JP JP2011514903A patent/JP5783042B2/ja not_active Expired - Fee Related
- 2011-03-31 EP EP11765738.7A patent/EP2562160B1/en not_active Not-in-force
- 2011-03-31 ES ES11765738.7T patent/ES2524400T3/es active Active
- 2011-03-31 AU AU2011237074A patent/AU2011237074B2/en not_active Ceased
- 2011-03-31 US US13/637,064 patent/US8642625B2/en active Active
- 2011-03-31 WO PCT/JP2011/058220 patent/WO2011125838A1/ja active Application Filing
- 2011-03-31 KR KR1020127023061A patent/KR101739879B1/ko active IP Right Grant
- 2011-03-31 MX MX2012010766A patent/MX2012010766A/es active IP Right Grant
- 2011-03-31 BR BR112012022944-3A patent/BR112012022944B1/pt not_active IP Right Cessation
- 2011-03-31 PL PL11765738T patent/PL2562160T3/pl unknown
- 2011-03-31 CA CA2793730A patent/CA2793730C/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2012010766A (es) | 2012-10-15 |
JPWO2011125838A1 (ja) | 2013-07-11 |
BR112012022944B1 (pt) | 2021-08-31 |
EP2562160A1 (en) | 2013-02-27 |
BR112012022944A2 (pt) | 2018-05-22 |
CN102812008B (zh) | 2015-01-07 |
AU2011237074B2 (en) | 2014-10-02 |
AU2011237074A1 (en) | 2012-10-18 |
ES2524400T3 (es) | 2014-12-09 |
US20130041157A1 (en) | 2013-02-14 |
JP5783042B2 (ja) | 2015-09-24 |
RU2012146323A (ru) | 2014-05-10 |
CN102812008A (zh) | 2012-12-05 |
KR20130052537A (ko) | 2013-05-22 |
EP2562160B1 (en) | 2014-09-10 |
EP2562160A4 (en) | 2013-08-07 |
WO2011125838A1 (ja) | 2011-10-13 |
CA2793730A1 (en) | 2011-10-13 |
KR101739879B1 (ko) | 2017-05-25 |
RU2559318C2 (ru) | 2015-08-10 |
CA2793730C (en) | 2017-10-17 |
US8642625B2 (en) | 2014-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181615T1 (hr) | Terapijsko sredstvo koje izaziva citotoksičnost | |
IL222702A0 (en) | Incontinence treatment | |
EP2548517A4 (en) | CATHETER FOR ENDOSCOPE | |
EP2448809A4 (en) | TRACK SYSTEM | |
GB2478797B (en) | Waste treatment | |
EP2621498A4 (en) | COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS | |
HK1247207A1 (zh) | 可治療癌症和其他疾病的新化合物 | |
EP2510949A4 (en) | THERAPEUTICS FOR FIBROMYALGIA | |
GB201109205D0 (en) | Urine shield | |
ZA201301458B (en) | Therapeutic agent for pain | |
PL2562160T3 (pl) | Środek leczniczy lub środek profilaktyczny do stosowania w zaburzeniach gromadzenia moczu | |
EP2601954A4 (en) | THERAPEUTIC FOR DISEASES | |
IL224340A (en) | Sanitary cause | |
EP2486929A4 (en) | ANTI-TUMOR THERAPEUTIC AGENT | |
GB0901465D0 (en) | Compounds for use in therapy | |
ZA201203961B (en) | Improved oestrus detector | |
GB2475242B (en) | Mounted medical device track system | |
ZA201201894B (en) | Pharmaceutical combination for treating tumor | |
PL2566579T3 (pl) | Urządzenie medyczne do magnetoterapii | |
IL218495A0 (en) | Theraputic agent for chronic pain | |
GB2486713B (en) | Pharmaceutical composition for treating urinary system disorders | |
TWM400880U (en) | Treatment device for waste solution | |
EP2409719A4 (en) | DETECTOR FOR INCONTINENCE | |
TWM388337U (en) | Defecation bed device for nursing | |
GB0920942D0 (en) | Agent for treating disease |